Keywords: Sanofi, Jevtana, Prostate cancer, Germany, IQWiG, AMNOG

Some advantages seen for Sanofi’s Jevtana by Germany’s IQWiG

Article | 25 January 2012

Print This

In an early benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG) has examined whether French ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in